<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04746287</url>
  </required_header>
  <id_info>
    <org_study_id>A96_01CMT1914</org_study_id>
    <nct_id>NCT04746287</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety and Tolerability of CKD-510 in Healthy Subjects</brief_title>
  <official_title>First-in-Human, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effects of CKD-510 in Single Ascending Dose and Multiple Ascending Dose in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-human study of CKD-510 in single-ascending dose and multiple-ascending&#xD;
      dose in healthy subjects. This trial is a randomized, double-blind, placebo-controlled study&#xD;
      to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics of food effects of&#xD;
      CKD-510.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 14, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Drug: CKD-510 Drug: Placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>[Part A, Part C] Number of subjects with adverse events (AEs)</measure>
    <time_frame>Treatment duration up to 4 days</time_frame>
    <description>The relationship of each adverse event to the investigational product was assessed by the investigator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>[Part A, Part C] Safety as assessed by vital signs</measure>
    <time_frame>Treatment duration up to 4 days</time_frame>
    <description>Symptoms of vital signs will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>[Part A, Part C] Safety as assessed by abbreviated physical examination parameters</measure>
    <time_frame>Treatment duration up to 4 days</time_frame>
    <description>Physical exmaination will include evaluation of main body systems/regions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>[Part A, Part C] Safety as assessed by electrocardiogram (ECG) parameters</measure>
    <time_frame>Treatment duration up to 4 days</time_frame>
    <description>12-lead ECGs will be obtained during the study using an ECG machine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>[Part A, Part C] Safety as assessed by biological analysis</measure>
    <time_frame>Treatment duration up to 4 days</time_frame>
    <description>Biological test will be obtained with assessments including hematology, biochemistry, urinalysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>[Part B] Composite of pharmacokinetics (PK) assessments of CKD-510</measure>
    <time_frame>3 days post dose</time_frame>
    <description>PK parameters include plasma concentrations of CKD-510, maximum observed plasma concentration (Cmax), time to Cmax (tmax), area under the plasma concentration-time curve (AUC) to last measurable concentration [AUC(0-t)], AUC through 24 hours [AUC(0-24)] and AUC per dosing interval [AUC(0-tau)], apparent terminal phase half-life following the last dose (t1/2) in fast or fed conditions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>[Part B] Composite of pharmacodynamics (PD) assessments of CKD-510</measure>
    <time_frame>3 days post dose</time_frame>
    <description>Change from baseline in acetylation of alpha-tubulin and histone as pharmacodynamics assessments after an administration of CKD-510 in fast or fed conditions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>[Part A, Part C] Maximum plasma concentration of CKD-510</measure>
    <time_frame>4 days post dose (SAD) or 17 days post dose (MAD)</time_frame>
    <description>Peak plasma concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>[Part A, Part C] Time of maximum plasma concentration of CKD-510</measure>
    <time_frame>4 days post dose (SAD) or 17 days post dose (MAD)</time_frame>
    <description>Time to reach Cmax (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>[Part A, Part C] Changes from baseline in plasma concentrations CKD-510 in time after dosing</measure>
    <time_frame>4 days post dose (SAD) or 17 days post dose (MAD)</time_frame>
    <description>Area under the concentration-time curve from time 0 extrapolated to the last quantifiable concentration at time t (AUC0-t)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>[Part A, Part C] Time of plasma elimination half-life of CKD-510</measure>
    <time_frame>4 days post dose (SAD) or 17 days post dose (MAD)</time_frame>
    <description>Apparent terminal elimination half-life (tÂ½)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>[Part A, Part C] Volume of distribution of CKD-510</measure>
    <time_frame>4 days post dose (SAD) or 17 days post dose (MAD)</time_frame>
    <description>Apparent volume of distribution during the terminal elimination phase (Vd/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>[Part A, Part C] Total plasma clearance of CKD-510</measure>
    <time_frame>4 days post dose (SAD) or 17 days post dose (MAD)</time_frame>
    <description>Apparent total plasma clearance (CL/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>[Part A, Part C] Pharmacodynamics assessments of CKD-510</measure>
    <time_frame>up to 2 days post dose (SAD) or 17 days post dose (MAD)</time_frame>
    <description>Change from baseline in acetylation of alpha-tubulin and histone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>[Part B] Number of subjects with adverse events (AEs)</measure>
    <time_frame>3 days post dose</time_frame>
    <description>The relationship of each adverse event to the investigational product was assessed by the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>[Part B] Safety as assessed by vital signs</measure>
    <time_frame>3 days post dose</time_frame>
    <description>Symptoms of vital signs will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>[Part B] Safety as assessed by abbreviated physical examination parameters</measure>
    <time_frame>3 days post dose</time_frame>
    <description>Physical exmaination will include evaluation of main body systems/regions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>[Part B] Safety as assessed by electrocardiogram (ECG) parameters</measure>
    <time_frame>3 days post dose</time_frame>
    <description>12-lead ECGs will be obtained during the study using an ECG machine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>[Part B] Safety as assessed by biological analysis</measure>
    <time_frame>3 days post dose</time_frame>
    <description>Biological test will be obtained with assessments including hematology, biochemistry, urinalysis.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dose administration (food Effect)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dose administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-510 single dose</intervention_name>
    <description>Investigational drug</description>
    <arm_group_label>Part A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-510 food effect</intervention_name>
    <description>Investigational drug</description>
    <arm_group_label>Part B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-510 multiple dose</intervention_name>
    <description>Investigational drug</description>
    <arm_group_label>Part C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male subject&#xD;
&#xD;
          -  Non-smoker subject or light smoker&#xD;
&#xD;
          -  Body mass index (BMI) between 18 and 30 kg/m2 inclusive at screening&#xD;
&#xD;
          -  Laboratory parameters within the normal range of the laboratory.&#xD;
&#xD;
          -  Male volunteers must be either vasectomized or agree to use a condom during the course&#xD;
             of the study and until 3 months (90 days) after the participant's last visit&#xD;
&#xD;
          -  Signing a written informed consent prior to selection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any history or presence of cardiovascular, pulmonary, gastro-intestinal, hepatic,&#xD;
             renal, metabolic, hematological, neurologic, psychiatric, systemic or infectious&#xD;
             disease&#xD;
&#xD;
          -  Blood donation within 2 months before administration&#xD;
&#xD;
          -  General anesthesia within 3 months before administration&#xD;
&#xD;
          -  Presence or history of drug hypersensitivity, or allergic disease&#xD;
&#xD;
          -  Any drug intake (except paracetamol or contraception) during the 28 days prior to the&#xD;
             first administration&#xD;
&#xD;
          -  History or presence of alcohol or drug abuse&#xD;
&#xD;
          -  Subject who, in the judgment of the Investigator, is likely to be non-compliant or&#xD;
             uncooperative during the study, or unable to cooperate because of a language problem,&#xD;
             poor mental development&#xD;
&#xD;
          -  Use of an investigational drug within 3 months (or 90 days) prior to Day1&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical site</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 15, 2021</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2021</study_first_posted>
  <last_update_submitted>February 15, 2021</last_update_submitted>
  <last_update_submitted_qc>February 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

